Advertisement
Canada markets closed

  • S&P/TSX

    22,259.16
    -31.46 (-0.14%)
     

  • S&P 500

    5,187.67
    -0.03 (-0.00%)
     

  • DOW

    39,056.39
    +172.13 (+0.44%)
     

  • CAD/USD

    0.7289
    +0.0002 (+0.03%)
     

  • CRUDE OIL

    79.22
    +0.84 (+1.07%)
     

  • Bitcoin CAD

    84,536.85
    -2,087.71 (-2.41%)
     

  • CMC Crypto 200

    1,307.04
    +12.37 (+0.96%)
     

  • GOLD FUTURES

    2,316.10
    -8.10 (-0.35%)
     

  • RUSSELL 2000

    2,055.14
    -9.51 (-0.46%)
     

  • 10-Yr Bond

    4.4920
    +0.0290 (+0.65%)
     

  • NASDAQ futures

    18,160.75
    -38.75 (-0.21%)
     

  • VOLATILITY

    13.00
    -0.23 (-1.74%)
     

  • FTSE

    8,354.05
    +40.38 (+0.49%)
     

  • NIKKEI 225

    38,202.37
    -632.73 (-1.63%)
     

  • CAD/EUR

    0.6778
    +0.0007 (+0.10%)
     

PepGen to Participate in Upcoming Investor Conferences

PepGen Inc.
·1 min read
PepGen Inc.
PepGen Inc.

BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that management will participate in the following upcoming investor conferences:

  • Stifel 2024 CNS Days (Virtual)

    • Tuesday, March 19, 2024, at 1:00 p.m. ET, Fireside Chat

  • Needham Annual Healthcare Conference (Virtual)

    • Monday, April 8, 2024, at 3:45 p.m. ET, Company presentation

A webcast of each conference presentation will be available on the “Events & Presentations” page within the Investors section of the PepGen website at https://investors.pepgen.com/. Replays of the webcasts will be available on the PepGen website for 90 days following the presentation dates.

ADVERTISEMENT

About PepGen

PepGen Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide, or EDO, platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases.

Investor Contact

Laurence Watts

Gilmartin Group

Laurence@gilmartinir.com


Media Contact

Sarah Sutton

Argot Partners

pepgen@argotpartners.com